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Abstract
Levetiracetam is a commonly used antiepileptic medication for tumor-related epilepsy. However, the 100 mL
intravenous (IV) infusion volume can be burdensome to imminently dying hospice patients. A reduced
infusion volume would improve patient tolerability. The purpose of this study was to evaluate the stability of
1000 mg/25 mL (40 mg/mL) levetiracetam IV solution in sodium chloride 0.9%. We prepared levetiracetam
40 mg/mL IV solution and added it to polyvinyl chloride (PVC) bags, polyolefin bags, and polypropylene
syringes. Triplicate samples of each product were stored at refrigeration (2–8°C) and analyzed on days 0, 1, 4,
7, and 14. Samples were subjected to visual inspection, pH measurement, and stability-indicating high-
performance liquid chromatography (HPLC) analysis. Over the 2-week storage period, there was no
significant change in visual appearance or pH for any of the stability samples. The HPLC results confirmed
that all stability samples retained 94.2–101.3% of initial drug concentration and no degradation products or
leachable material from the packaging materials were observed. We conclude that levetiracetam 1000 mg/25
mL IV solution in sodium chloride 0.9% is physically and chemically stable for up to 14 days under
refrigeration in polypropylene syringes, PVC bags, and polyolefin bags.
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ABSTRACT 
 Levetiracetam is a commonly used antiepileptic medication for tumor-related epilepsy. 
However the 100 mL intravenous (IV) infusion volume can be burdensome to imminently dying 
hospice patients. A reduced infusion volume would improve patient tolerability. The purpose of 
this study was to evaluate the stability of 1000 mg/25 mL (40 mg/mL) levetiracetam IV solution 
in sodium chloride 0.9%. We prepared levetiracetam 40 mg/mL IV solution and added it to 
polyvinyl chloride (PVC) bags, polyolefin bags, and polypropylene syringes. Triplicate samples 
of each product were stored at refrigeration (2-8°C) and analyzed on days 0, 1, 4, 7, and 14. 
Samples were subjected to visual inspection, pH measurement, and stability-indicating high 
performance liquid chromatography (HPLC) analysis.  Over the two-week storage period, there 
was no significant change in visual  
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appearance or pH for any of the stability samples.  The HPLC results confirmed that all stability 
samples retained 94.2-101.3% of initial drug concentration and no degradation products or 
leachables from the packaging materials were observed.  We conclude that levetiracetam 1000 
mg/25 mL IV solution in sodium chloride 0.9% is physically and chemically stable for up to 14 
days under refrigeration in polypropylene syringes, PVC bags, and polyolefin bags. 
 
KEYWORDS:  intravenous, levetiracetam, concentrated, stability, epilepsy, seizures, pain, 
neuropathic 
 
INTRODUCTION 
 Seizures are a common symptom of patients suffering from brain tumors.  Approximately 
20-40% of all brain tumor patients have a seizure during the course of their disease.1 Tumoral 
epilepsy has an adverse impact on quality of life due to the unpredictable nature and 
psychological effects of the disease.2 Imminently dying patients frequently experience dysphagia 
and often require a switch from oral to parenteral antiepileptic drugs to prevent additional tumor-
associated seizures.  
 Levetiracetam is an antiepileptic drug indicated as adjunct therapy for partial onset and 
myoclonic seizures in adults. It is effective at decreasing seizure frequency in tumor-related 
epilepsy and has a favorable pharmacokinetic profile with few drug interactions.2-4 
Levetiracetam is also used to treat neuropathic pain.5-8  It is commercially available as an 
injectable solution for patients with dysphagia.9,10 The levetiracetam 500 mg/5 mL vials are 
typically diluted in 100 mL of compatible diluent to achieve a 500 mg, 1000 mg or 1500 mg 
dose.9 The dose is administered as a 15-minute intravenous infusion. For ease of preparation 
ready-to-administer levetiracetam bags in 500 mg/100 mL, 1000 mg/100 mL, or 1500 mg/100 
mL in sodium chloride 0.9% became available in recent years.10 
 Administration of 100 mL of fluid multiple times a day can be burdensome to imminently 
dying hospice patients by potentially worsening edema, nausea/vomiting, and respiratory 
secretions resulting in patient discomfort. Weighing the clinical risks and benefits of continuing 
IV levetiracetam versus switching to an alternate parenteral antiepileptic drug (AED) with less 
administration volume can be challenging for providers. If the same IV levetiracetam dose could 
be administered in a smaller volume, it may improve patient tolerability. Unfortunately, there is 
no published levetiracetam stability data beyond the maximum commercially available 15 
mg/mL strength. The stability of 40 mg/mL levetiracetam was mentioned in a reference 
handbook for 24 hours at controlled room temperature, but it was based on unpublished personal 
communication.11   The purpose of this pilot study was to evaluate the stability of levetiracetam 
1000 mg/25 mL (40 mg/mL) in sodium chloride 0.9% packaged in polypropylene syringes, 
polyvinyl chloride (PVC) and polyolefin bags under refrigeration for up to 14 days. 
MATERIALS AND METHODS 
 Materials 
 Levetiracetam injection 500 mg/5 mL vials were purchased from Hospira, Lake Forest, 
IL, NDC#0409-1886-02. The diluent, sodium chloride 0.9% injection was purchased from 
Baxter, Deerfield, IL, NDC#0338-0049-02. The empty 50 mL sterile polyolefin bags were 
purchased from Baxter, Deerfield, IL, product code 2B8019, and the 30 mL polypropylene 
syringes were purchased from BD, Franklin Lakes, NJ, product code 302832. Empty sterile PVC 
bags were not available commercially. Therefore, the 25 mL sodium chloride 0.9% injection 
PVC bags were used (Hospira, Lake Forest, IL, NDC#0409-7984-20). The fluid in these bags 
was completely removed prior to the addition of the 40 mg/mL levetiracetam solution. HPLC 
standards were prepared using levetiracetam powder, 99.79% purity, purchased from PCCA, 
Houston, TX, lot C159856. Phosphoric acid and acetonitrile used for the HPLC analysis were 
purchased from Fisher Scientific, Fairlawn, NJ, lot# 068114 and 110762, respectively. 
 Stability Samples 
 Under aseptic conditions, a 250 mL batch of 40 mg/ml levetiracetam was prepared by 
mixing 100 mL (20 vials) of commercially available levetiracetam 500 mg/5 mL injection with 
150 mL of sodium chloride 0.9% in a 250 mL beaker. The 40 mg/mL levetiracetam solution was 
aseptically transferred into PVC bags, polyolefin bags, and polypropylene syringes, each 
containing 25 mL. Three replicates of each packaging were prepared, yielding a total of nine 
stability samples. All samples were sealed properly after the addition of the levetiracetam 
solution. All stability samples were stored at refrigeration (2 – 8°C). The batch preparation 
approach was used to ensure the uniformity of the initial concentration for all stability samples. 
Appropriate compounding procedures for actual dispensing are recommended in the discussion 
section.   
 Stability assessment was performed immediately after preparation (time zero), and at 
days 1, 4, 7 and 14. The bags and syringes were visually inspected at each time point for color, 
clarity, microbial growth, and particulates. A 1 mL sample was then withdrawn aseptically from 
each stability sample. A 200 μL aliquot from each sample was diluted with purified water in a 50 
mL volumetric flask and analyzed by a stability-indicating high performance liquid 
chromatography (HPLC) method; three injections were performed for each of the triplicate 
samples. The remainder of the 1 mL sample was used for pH measurement (SevenEasy pH 
meter, Mettler-Toledo Inc., Columbus, OH). The stability samples were re-sealed and 
immediately returned to the refrigerator. Since the study focus was physical and chemical 
stability, sterility was not required or tested.   
 Stability-indicating HPLC Analysis 
 The stability-indicating HPLC analysis was performed using a Shimadzu model LC-
2010AHT instrument (Shimadzu Scientific Instruments, Marlborough, MA). The 
chromatographic variables used were from a previous stability-indicating assay established in the 
same lab.13 The HPLC column (ODS AQ, 5 μm, 250 × 4.6 mm, YMC America, Inc., Allentown, 
PA) was maintained at 30°C throughout the analysis. The mobile phase consisted of 0.1% 
aqueous phosphoric acid and acetonitrile at a volume-to-volume ratio of 85:15 with a flow rate 
of 1.0 mL/min. Each injection volume was 10 μL, and the UV detection wavelength was set at 
205 nm. Under these conditions, the levetiracetam retention time was approximately 5.2 minutes 
(Figure 1).  
 Standards of levetiracetam solutions were prepared for each time point for calibration 
purposes. A 10 mg/mL stock solution was prepared by dissolving the calculated amount of 
levetiracetam powder in purified water and standard solutions of 0.08. 0.12, 0.16, 0.20, 0.24 
mg/mL were made by further dilutions into 100 mL volumetric flasks. A calibration curve was 
constructed at each time point by linear regression of the peak area of levetiracetam against 
levetiracetam concentration. The curves were found to be linear over the concentration range of 
the standards (r2 = 0.996 or better). Intraday and interday coefficients of variation were within 
1.00%. 
RESULTS  
 At study initiation, the physical appearance of the compounded levetiracetam solution 
was clear, colorless, and free of particulate matter. Results of the chemical stability tests of pH 
and drug concentration are reported in Table 1 and 2 respectively.  The pH values were 
consistent with the pH of the source levetiracetam product which was buffered at approximately 
pH 5.5 with acetic acid and sodium acetate.10 The HPLC results indicated that the drug 
concentration were 4 – 8% higher than the nominal value of 40 mg/mL. This could be ascribed to 
the approximate nature of the compounding procedures (e.g. syringe accuracy) and potency 
range of the source products acceptable by the manufacturer. The drug concentration in the PVC 
bags was also slightly lower than that in the polyolefin bags or polypropylene syringes, which 
was most likely due to the residual sodium chloride 0.9% injection in the PVC bags. 
Nevertheless, all initial concentration values were within the ± 10% of the nominal value and 
were therefore considered acceptable for the study. For the remaining time points, the HPLC data 
were reported as percent initial concentration remaining. Levetiracetam was considered stable if 
the solution retained 90-110% initial drug concentration with no significant new peaks observed. 
 Over the two-week study period, all samples remained clear, colorless, and free of visible 
precipitation or microbial growth. No significant changes in the pH of any of the samples were 
observed (Table 1). The stability-indicating HPLC analysis also confirmed that all samples 
retained 94.2-101.3% of the initial drug concentration (Table 2). No new peaks, due to 
degradation products or leachables, were observed in the HPLC chromatograms. 
 
DISCUSSION 
USP General Chapter <1191> discusses the general stability considerations in dispensing 
practice.13 Levetiracetam is a simple organic molecule with relatively stable functional 
groups.9,12,14  The main concern with the compounded levetiracetam 40 mg/mL parenteral 
solution was potential drug adsorption to packaging materials and leachables from the same. This 
study evaluated three packaging materials for the following reasons. The PVC bags are the most 
commonly used IV bags in health systems and they are recommended by the manufacturer.9 
However, the use of PVC bags is becoming unfavorable in recent years due to environmental 
concerns of PVC incineration byproducts and potential health risks associated with the 
plasticizers.15,16  Polyolefin bags are an alternative that hospitals can use if PVC-free bags are 
preferred. In addition, empty 50-mL polyolefin IV are available commercially, while empty 50-
mL (or below) PVC bags are not readily available. Polypropylene syringes were included in this 
study in case the use of an infusion pump is desired. Based on the study results, levetiracetam 40 
mg/mL parenteral solution is stable and compatible in all three packaging materials evaluated. 
 A 250 mL batch of 40 mg/mL levetiracetam solution was initially prepared in this pilot 
study to achieve a consistent starting drug concentration across all stability samples. To reduce 
contamination and eliminate the need for sterilization, the actual IV admixture products for 
patient use should be prepared as individual doses directly in the IV bags or syringes. Since this 
is a compounded sterile preparation, the pharmacy must follow all pertinent requirements 
specified in USP <797>, and assign Beyond Use Dating accordingly.17   
 
CONCLUSIONS 
 It is of great importance to provide comfort and symptom management to terminally ill 
patients in their final days. A 1000 mg/25 mL levetiracetam IV solution would be beneficial to 
hospice patients with tumoral epilepsy who cannot tolerate the commercially available 100 mL 
volume. These pilot study results confirm that levetiracetam 1000 mg/25 mL IV solution in 
sodium chloride 0.9% injection is physically and chemically stable for up to 14 days under 
refrigeration (2-8°C) in polypropylene syringes, PVC bags, and polyolefin bags. Proper sterile 
compounding practice as per USP <797> must be followed when making the actual IV 
admixture preparations to be used in patients. 
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Table 1. pH Results of Levetiracetam Solution Stability Samples (n = 3) 
 
Packaging 
pH (Mean ± SD) 
Time 0 1 day 4 days 7 days 14 days 
PVC bag 5.45 ± 0.42 5.41 ± 0.64 5.42 ± 0.11 5.38 ± 1.11 5.51 ± 0.74 
Polyolefin bag 5.43 ± 0.53 5.37 ± 0.87 5.42 ± 0.11 5.30 ± 0.11 5.39 ± 0.32 
Polypropylene 
Syringe 5.44 ± 0.38 5.36 ± 0.74 5.40 ± 0.53 5.29 ± 0.11 5.41 ± 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. HPLC Results of Levetiracetam Solution Stability Samples (n = 3) 
 
Packaging 
Initial Drug 
Concentration 
(mg/mL) 
% Initial concentration remaining (Mean ± SD) 
1 day 4 days 7 days 14 days 
PVC bag 41.7 ± 0.8 98.2 ± 0.7 97.5 ± 1.2 95.8 ± 0.7 94.2 ± 0.9 
Polyolefin bag 43.2 ± 1.2 99.7 ± 1.6 98.3 ± 0.5 96.8 ± 5.4 95.8 ± 2.4 
Polypropylene 
Syringe 42.9 ± 0.2 101.3 ± 2.2 100.7 ± 0.7 96.0 ± 0.9 94.6 ± 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A representative chromatogram of levetiracetam showing the active peak at 5.2 
minutes. 
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